Skip to main content

This column was originally published on RealMoney on Aug. 23 at 8:43 a.m. EDT. It's being republished as a bonus for readers.

Can't figure out how some stocks get so hated. Take this



. The short position has doubled in the last few months. Doubled! All because the scrips for its new diabetes drug Byetta may not be as good as thought.

I approach Amylin totally differently from the shorts. For some reason -- I think because it is an epidemic -- I have a lot of friends who have diabetes. Any positive for them, I cheer. It's a tough disease. When Byetta hit the market, I went out hard on Amylin, saying it should be bought. The catcalls started almost immediately, and

any time

the stock lifted, I saw shorts trying to knock the thing down, selling it below the bid, making it heavy at every turn.

Last night, Amylin revealed that it might have a once-a-week injectible for diabetes. The shorts weren't thinking about the possibility. Today, I see them going nuts -- the stock is much higher than it was -- covering the darned thing in early morning trading. (Only crazed short-sellers buy stocks up $6.)

What should you do if you have been listening to me on Amylin? I would sell the stock, that's what I would do, at least half the position, and play with the house's money for the rest. Think about it: This injectible is something that won't hit the market for a couple of years. You have time. Sell into the shorts' panic.

Image placeholder title

But remember, any company working on diabetes is, per se, a company you should consider because the market is much more huge than most people realize. The Amylin shorts learned that today.

Sobering lesson.

P.S. from Editor-in-Chief, Dave Morrow:

Scroll to Continue

TheStreet Recommends

It's always been my opinion that it pays to have more -- not fewer -- expert market views and analyses when you're making investing or trading decisions. That's why I recommend you take advantage of our

free trial offer



premium Web site, where you'll get in-depth commentary


money-making strategies from over 50 Wall Street pros, including Jim Cramer. Take my advice --

try it now.

James J. Cramer is a director and co-founder of He contributes daily market commentary for's sites and serves as an adviser to the company's CEO. Outside contributing columnists for and, including Cramer, may, from time to time, write about stocks in which they have a position. In such cases, appropriate disclosure is made. To see his personal portfolio and find out what trades Cramer will make before he makes them, sign up for ActionAlertsPLUS by

clicking here. While he cannot provide personalized investment advice or recommendations, he invites you to send comments on his column by

clicking here. Listen to Cramer's RealMoney Radio show on your computer; just click

here. Watch Cramer on "Mad Money" at 6 p.m. ET weeknights on CNBC. Click

here to order Cramer's latest book, "Real Money: Sane Investing in an Insane World," click

here to get his second book, "You Got Screwed!" and click

here to order Cramer's autobiography, "Confessions of a Street Addict."